Research Article
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
Table 2
Velacur™ and FibroScan® assessments of LSM and attenuation parameters in healthy controls and patients.
| | Healthy | Patients (all) | value (where applicable) | Patients (NAFLD) | Patients (HCV SVR) | value (where applicable) |
| | 54 | 79 | | 54 | 25 | | | Velacur™ stiffness | | | <0.0001. | | | 0.036 | | FibroScan® stiffness | | | <0.0001 | | | 0.202 | | FibroScan® probe used | (92%), | (47%), | <0.0001 | (37%), | (72%), | 0.0025 | | Velacur™ ACE | | | <0.0001 | | | 0.084 | | FibroScan® CAP | | | <0.0001 | | | <0.0001 |
|
|
